Medicare Enrolled
Dr. Syed Akhtar, M.D.
Medical Oncology · Beaumont, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Akhtar from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Akhtar? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Akhtar
Dr. Syed Akhtar is a medical oncology in Beaumont, TX, with 19 years in practice. Based on federal Medicare data, Dr. Akhtar performed 111,847 Medicare services across 3,305 unique beneficiaries.
Between the years covered by Open Payments, Dr. Akhtar received a total of $2,026 from 33 pharmaceutical and/or device companies across 82 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Akhtar is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 7% volume in TX$ $2,026 industry payments
Medicare Practice Summary
Medicare Utilization ↗111,847
Medicare services
Top 7% in TX for medical oncology
3,305
Unique beneficiaries
$3
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~5,887 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 33,150 | $0 | $5 |
| Iron sucrose injection (Venofer) | 29,300 | $0 | $2 |
| Anti-nausea injection (fosaprepitant) | 17,700 | $0 | $5 |
| Paclitaxel chemotherapy injection | 11,779 | $0 | $8 |
| Denosumab injection (Prolia/Xgeva) | 2,940 | $19 | $66 |
| Dexamethasone injection (steroid) | 2,505 | $0 | $1 |
| Contrast dye for imaging (iodine-based) | 1,900 | $0 | $3 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,450 | $1 | $114 |
| Injection, leucovorin calcium, per 50 mg | 993 | $3 | $25 |
| Injection, fluorouracil, 500 mg | 822 | $2 | $13 |
| Comprehensive metabolic blood panel | 770 | $10 | $64 |
| Blood draw (venipuncture) | 754 | $8 | $20 |
| Complete blood count (CBC) with differential | 740 | $8 | $36 |
| Office visit, established patient (20-29 min) | 608 | $62 | $250 |
| Injection, magnesium sulfate, per 500 mg | 510 | $1 | $6 |
| Injection, granisetron hydrochloride, 100 mcg | 480 | $0 | $24 |
| Office visit, established patient (30-39 min) | 444 | $92 | $368 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 399 | $21 | $157 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 356 | $45 | $313 |
| Administration of chemotherapy into vein, 1 hour or less | 316 | $95 | $707 |
| Injection of additional new drug or substance into vein | 300 | $11 | $108 |
| Injection, carboplatin, 50 mg | 291 | $2 | $300 |
| Iron level test | 251 | $6 | $27 |
| Iron binding capacity test | 250 | $9 | $35 |
| Drug injection, under skin or into muscle | 218 | $10 | $96 |
| Injection, zoledronic acid, 1 mg | 209 | $6 | $431 |
| Blood count, hemoglobin | 200 | $2 | $14 |
| Complete blood count (CBC), automated | 139 | $6 | $34 |
| Microscopic examination for white blood cells with manual cell count | 138 | $4 | $22 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 137 | $15 | $100 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 135 | $24 | $145 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 111 | $54 | $211 |
| Administration of chemotherapy into vein, each additional hour | 106 | $21 | $161 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 101 | $133 | $3,675 |
| Administration of additional new drug or substance into vein, 1 hour or less | 97 | $47 | $344 |
| Injection, diphenhydramine hcl, up to 50 mg | 95 | $1 | $7 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 85 | $122 | $500 |
| Hospital follow-up visit, low complexity | 84 | $38 | $135 |
| Administration of additional new drug or substance into vein using push technique | 80 | $41 | $289 |
| Reticulated (young) platelet measurement | 75 | $35 | $143 |
| Hospital follow-up visit, moderate complexity | 63 | $59 | $247 |
| Unclassified drugs | 62 | $1 | $8 |
| Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 53 | $70 | $70 |
| Infusion, normal saline solution , 1000 cc | 47 | $2 | $19 |
| New patient office visit (45-59 min) | 45 | $115 | $565 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 43 | $1,078 | $4,802 |
| Ferritin level test (iron stores) | 43 | $13 | $60 |
| Stool analysis for blood to screen for colon tumors | 42 | $4 | $24 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 42 | $91 | $657 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 41 | $15 | $94 |
| Hospital follow-up visit, high complexity | 40 | $88 | $357 |
| Injection, lorazepam, 2 mg | 37 | $1 | $3 |
| Irrigation of implanted venous access drug delivery device | 36 | $18 | $114 |
| Infusion into a vein for hydration, each additional hour | 33 | $9 | $75 |
| New patient office visit (30-44 min) | 32 | $71 | $372 |
| Drawing of blood for a medical problem | 24 | $67 | $264 |
| Initial hospital admission, moderate complexity | 23 | $99 | $470 |
| Blood creatinine level | 19 | $5 | $31 |
| Urea nitrogen level to assess kidney function, quantitative | 19 | $4 | $24 |
| Uric acid level test | 16 | $4 | $25 |
| CT scan of abdomen and pelvis with contrast | 14 | $161 | $1,067 |
| Infusion into a vein for hydration, 31-60 minutes | 14 | $24 | $256 |
| Office visit, established patient, complex (40-54 min) | 14 | $119 | $496 |
| Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 14 | $264 | $2,762 |
| Ct scan of chest with contrast | 13 | $45 | $821 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
30.6% high complexity
64.6% medium
4.8% routine
Industry Payment Transparency
Open Payments through 2024 ↗$2,026
Total received (2018-2024)
Avg $289/year across 7 years
Bottom 38% in TX for medical oncology
33
Companies
82
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$1,567 (77.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$459 (22.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$1,162
2023$327
2022$38
2021$12
2020$78
2019$146
2018$263
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Astellas Pharma US Inc
$281
Novartis Pharmaceuticals Corporation
$145
AstraZeneca Pharmaceuticals LP
$131
Daiichi Sankyo Inc.
$104
Lilly USA, LLC
$94
Boehringer Ingelheim Pharmaceuticals, Inc.
$90
PFIZER INC.
$89
Janssen Biotech, Inc.
$87
E.R. Squibb & Sons, L.L.C.
$87
Seagen Inc.
$80
GENZYME CORPORATION
$74
JAZZ PHARMACEUTICALS INC.
$70
Gilead Sciences, Inc.
$63
Tempus AI, Inc
$58
Puma Biotechnology, Inc.
$51
BeiGene USA, Inc.
$47
Eisai Inc.
$46
Celgene Corporation
$41
SOBI, INC
$39
Merck Sharp & Dohme LLC
$38
Regeneron Healthcare Solutions, Inc.
$37
Incyte Corporation
$35
Janssen Pharmaceuticals, Inc
$32
PharmaEssentia USA Corporation
$29
Rigel Pharmaceuticals, Inc.
$25
Kite Pharma, Inc.
$24
Genmab U.S., Inc.
$23
EMD Serono, Inc.
$22
PUMA BIOTECHNOLOGY, INC.
$21
Genentech USA, Inc.
$21
Agios Pharmaceuticals, Inc.
$20
Deciphera Pharmaceuticals Inc.
$13
Takeda Pharmaceuticals U.S.A., Inc.
$12
Top 3 companies account for 27.5% of total payments
Associated products mentioned in payments ›
ALIMTA · BAVENCIO · BESREMI · BRUKINSA · CALQUENCE · Doptelet · ENJAYMO · ERLEADA · Enhertu · Epkinly · Erleada · Fabhalta · GILOTRIF · IBRANCE · IMFINZI · INLYTA · JAKAFI · KEYTRUDA · LIBTAYO · LYNPARZA · Lenvima · NERLYNX · NINLARO · OPDIVO · OPDUALAG · PADCEV · PYRUKYND · Padcev · QINLOCK · REBLOZYL · RYBREVANT · Rezlidhia · Rozlytrek · SARCLISA · SCEMBLIX · TECVAYLI · VERZENIO · XT CDX · XTANDI · Xtandi · Yescarta · ZEPZELCA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (77%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $2 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
6
Per 100K population
2.4
County median income
$59,934
Nearest hospital
CHRISTUS SOUTHEAST TEXAS- ST ELIZABETH
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Akhtar is a mixed practice specialist, with above-average Medicare volume (top 7% in TX), and low-engagement industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Akhtar experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Akhtar performed 33,150 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Akhtar receive payments from pharmaceutical companies?
Yes. Dr. Akhtar received a total of $2,026 from 33 companies across 82 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Akhtar's costs compare to other medical oncologys in Beaumont?
Dr. Akhtar's average Medicare payment per service is $3. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Akhtar) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Beaumont
Browse medical oncologys in Beaumont ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in TX
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in TX
Which TX medical oncologys receive the most from drug and device companies.
By company
Astellas Pharma US Inc Payments to Doctors
See all physicians who received payments from Astellas Pharma US Inc.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology